HIF1A and hepatocellular carcinoma: By binding with HIF1α, FASN promotes HIF1α nuclear translocation, inhibits HIF1α ubiquitination and proteasome degradation, and then enhances the transcription of carrier family 7 member 11 (SLC7A11), enhancing the iron death resistance of hepatocellular carcinoma cells induced by sorafenib [223].